Nature’s Sunshine Products Inc.’s initiative targeting 100% solar power for its US manufacturing facility and warehouses began in 2021 with a vice president at the herbal and nutritional supplement direct seller talking with the CEO.
Nature’s Sunshine Looks For Cost Savings To Rise Over Long Haul Switching To Sustainable Energy
Herbal and nutritional supplement direct seller has reached 85% solar power use at its US facilities while also reducing landfill waste from those sites more than 90%, cutting its US shipping routes by half and consolidating four distribution centers in Europe into one operating on wind power.
More from ESG
• By
“Protecting the environment is a shared responsibility. It is unfair to expect only two sectors to fund wastewater treatment modernization and operation,” argues AESGP director general Jurate Švarcaite.
• By
Perrigo's retail customers are expecting real "net zero" progress from consumer health manufacturers, which is in turn driving the firm's sustainability ambitions and expectations from their own suppliers, Perrigo’s UK ethical compliance lead Isobel Gay tells HBW Insight in this exclusive interview.
• By
Pharmaceutical industry associations are united in their view that the revised EU Urban Wastewater Treatment Directive discriminates against medicines and cosmetics producers.
• By
Kenvue's EMEA and LATAM head Carlton Lawson acknowledges the urgency of environmental issues like antimicrobial resistance and wastewater pollution in this interview with HBW Insight, but calls for a more balanced approach on the part of European regulators.
More from HBW Insight
• By
A round-up of the latest industry moves in Europe: Pharma Deutschland elects board of new Brussels operation; MHRA's new CEO gets to work; Futura names non-executive director.
• By
“If this doesn’t get reauthorized, look at the number of the ingredients out there, the number of products, what would happen all those products out there for the consumer, on that shelf, in the drugstore or someplace?” says Rep. Bob Latta during House hearing.
• By
Energy and Commerce Health Subcommittee Democrats focus on criticizing HHS Secretary Kennedy’s RIF announcement, including 3,500 FDA jobs among cuts across HHS agencies. “If we reauthorize it, will it continue?” Texas representative Lizzie Fletcher asks of OMUFA.